The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like ...

Explore medication options for kidney disease and potential side effects. Learn the best treatment options to slow ...

Investigators studied the prevalence and outcomes of venous thromboembolic events (VTEs) among hospitalized patients with and without CKD.

I n an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top executives met, like they had dozens of times before, to hear the ...